AstraZeneca, Conformetrix in discovery deal

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Conformetrix Ltd. (Manchester, U.K.) partnered to use Conformetrix's NMR-based technology to enhance lead discovery and hit identification in AstraZeneca's preclinical pipeline. Under the two-year deal, Conformetrix will also use its technology to determine the bioactive conformations of naturally occurring ligands as templates for library enhancement and hit identification. Conformetrix will receive an undisclosed upfront payment and research funding, and is eligible for milestones. The work will be managed by a joint research team. ...